Sun Pharmaceutical Industries Limited reported a strong financial performance for the financial year ended March 31, 2026, with consolidated revenues growing by 11.9% to ₹582,201 million. EBITDA increased by 16.1% to ₹177,314 million, reflecting operational strength and margin expansion, while net profit after minority interest grew by 5% to ₹114,794 million. The company maintained its position as the largest pharmaceutical company in India with an 8.4% market share, according to AIOCD AWACS MAT March 2026 data.

Financial Highlights

The company reported an adjusted net profit after minority interests of ₹124,015 million and increased its net worth to ₹835,701 million. R&D expenditure for the year stood at ₹35,540 million, representing 6.1% of sales. The innovative medicines business accounted for 22% of consolidated sales.

Operational Performance

The India formulation business recorded a 14% increase in sales to ₹192,904 million, contributing 33% of consolidated revenues. This growth was driven by chronic therapies, new product launches, and deeper market reach. The company entered the GLP-1 receptor agonist category in India with the launch of semaglutide under the brand names Noveltreat and Sematrinity. In the US, sales dipped slightly by 0.9% to ₹168,242 million, where growth in innovative medicines offset the decline in the generics business. Emerging markets performed well, supported by innovative medicines and strengthening commercial capabilities, recording an 18.8% sales growth to ₹111,865 million.

The company continued to invest in innovation, bringing two new treatments, LEQSELVI and UNLOXCYT, to market during the year. Sun Pharmaceutical Industries Limited also announced an agreement to acquire Organon to strengthen its global innovative medicines portfolio.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE044A01036/b95f130aea384791.pdf

Sun Pharmaceutical Industries Limited will hold its 34th Annual General Meeting on Friday, July 31, 2026, at 4:00 P.M. IST via video conferencing. The Board of Directors has recommended a final dividend of ₹5 per equity share of face value ₹1 each for the financial year 2025-26. This dividend is subject to the approval of members at the ensuing AGM.

The company has fixed Tuesday, July 7, 2026, as the record date to determine the members eligible to receive the dividend. Shareholders holding shares as on this date will receive the payment electronically, provided their bank details are updated with the depository participant or the company's Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited.

Members holding shares in physical form must update their KYC details, including PAN, contact details, nomination, bank account details, and specimen signature, in accordance with a SEBI circular dated June 10, 2024. Failure to meet these KYC requirements, excluding the non-submission of a choice of nomination, will result in the inability to receive dividends.

The Notice of the 34th AGM along with the Annual Report for the financial year 2025-26 will be sent electronically to members whose email addresses are registered with the RTA or depositories. These documents will also be available on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited.

Members will have the opportunity to cast their votes remotely on the business set forth in the Notice through remote e-voting. The facility for e-voting will also be provided at the AGM for members attending the meeting who have not cast their votes remotely. Central Depository Services (India) Limited (CDSL) has been appointed as the agency for providing the e-voting facility.